EP2596827A2 — Airflow adaptor for a breath-actuated dry powder inhaler
Assigned to Norton Healthcare Ltd · Expires 2013-05-29 · 13y expired
What this patent protects
A deagglomerator for a breath-actuated dry powder inhaler comprising: an airflow adaptor (500); an inner wall (512) defining a swirl chamber (514); a dry powder supply port (522) in the first end (518) of the swirl chamber; at least one inlet port (524,525) in the inner wall of t…
USPTO Abstract
A deagglomerator for a breath-actuated dry powder inhaler comprising: an airflow adaptor (500); an inner wall (512) defining a swirl chamber (514); a dry powder supply port (522) in the first end (518) of the swirl chamber; at least one inlet port (524,525) in the inner wall of the swirl chamber adjacent to the first end of the swirl chamber providing fluid communication between a region exterior to the deagglomerator and the first end of the swirl chamber; an outlet port providing fluid communication between the second end (520) and the airflow adaptor (501); and wherein the airflow adaptor comprises at least one swirl chamber by-pass port (502,503,504,505) for allowing air to flow from a proximal end of the airflow adaptor to a distal end of the airflow adaptor independently of the swirl-chamber when a breath-induced low pressure is applied to the distal end of the airflow adaptor.
Drugs covered by this patent
- Cutivate (FLUTICASONE PROPIONATE) · Teva Pharm
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.